Summit Creek Advisors LLC Takes Position in TransMedics Group, Inc. $TMDX

Summit Creek Advisors LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the second quarter, HoldingsChannel reports. The fund acquired 26,707 shares of the company’s stock, valued at approximately $1,774,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hussman Strategic Advisors Inc. bought a new stake in shares of TransMedics Group in the fourth quarter worth $1,788,000. Candriam S.C.A. increased its position in TransMedics Group by 45.4% during the first quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock valued at $15,783,000 after acquiring an additional 49,580 shares during the last quarter. M&T Bank Corp lifted its holdings in TransMedics Group by 749.2% in the fourth quarter. M&T Bank Corp now owns 18,572 shares of the company’s stock valued at $2,259,000 after acquiring an additional 16,385 shares during the period. Regency Capital Management Inc. DE purchased a new position in TransMedics Group in the first quarter worth about $2,172,000. Finally, Geneos Wealth Management Inc. purchased a new position in TransMedics Group in the first quarter worth about $3,045,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TMDX opened at $90.69 on Wednesday. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The business has a 50-day simple moving average of $76.32 and a two-hundred day simple moving average of $95.94. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of 23.31 and a beta of 1.90. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The company had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. During the same period last year, the business earned $0.92 EPS. The firm’s quarterly revenue was up 20.7% compared to the same quarter last year. On average, analysts expect that TransMedics Group, Inc. will post 1.47 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Stifel Nicolaus upped their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, June 18th. UBS Group dropped their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Finally, TD Cowen reiterated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research report on Wednesday, July 1st. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $124.18.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.